Telix to Buy Isotope Maker ITM for Up to $2.35 Billion

Telix Pharmaceuticals (NASDAQ:TLX) agreed on September 21 to acquire ITM Isotope Technologies Munich SE for up to $2.35 billion, paying $1.65 billion upfront before cash and debt. Another $700 million follows only if ITM's lead drug wins approval and hits sales targets.

Telix will pay mostly in its own stock. The company will issue 105.8 million new shares, with the balance of the deal made up of ITM debt it assumes, transaction costs, and rolled-over management equity. The transaction requires approval from Telix shareholders and regulators and should close by the end of the year.

Why an isotope supplier is worth $2.35 billion

Radiopharmaceuticals treat cancer by delivering radiation directly to tumours. The approach has a built-in constraint: the radioactive isotope decays within days, so a dose only works if the material arrives in time. For Telix, isotope supply has mattered as much as trial results, because a delayed shipment ruins a dose that good clinical data cannot rescue.

ITM makes lutetium-177, one of the isotopes the field runs on. Telix says ITM is also the main outside supplier of that isotope to Pluvicto, the Novartis drug competing with what Telix is building.

Until now, Telix has bought its isotopes from outside suppliers, ITM among them. After this deal, it makes them itself. Vertical integration removes a supplier margin and a scheduling risk. It also puts Telix on the other side of a competitor's supply chain — which is precisely the part regulators will examine.

The drug attached to the factory

The acquisition is not only about manufacturing. The deal also buys ITM-11, a drug that beat its trial endpoint but has not cleared the FDA. ITM-11 extended progression-free survival to 23.9 months in gastroenteropancreatic neuroendocrine tumours, well beyond the comparator. The only approved radiopharmaceutical rival in that space is Novartis's Lutathera.

The $700 million in milestone payments splits between regulatory approval and later sales. Telix pays the bulk of the price upfront and the remainder only if the medicine gets through.

Shareholders absorb the cost first

The 105.8 million new shares are the immediate cost of the deal, and dilution lands on holders before any of the anticipated benefits arrive. A buyer with pricing power would typically wait for an FDA resubmission before paying, and Telix did not.

The market rendered its verdict quickly. The stock fell about 10% in New York on the announcement and dropped more than that in Sydney, before recovering some ground the next day.

Two approvals still stand between announcement and close: one from shareholders, one from regulators. A stock-funded deal asks holders to accept dilution up front, so the vote is not a formality. And owning the main outside supplier of a competitor's isotope is exactly the kind of arrangement antitrust authorities scrutinize closely.

If both clearances come through, Telix ends the year controlling its own lutetium-177 supply, a Phase-stage asset in neuroendocrine tumours, and a supplier relationship with its largest competitor — a combination that will test whether vertical integration in radiopharmaceuticals justifies its price.